Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377048 | 0.84 | ROCK2 (0.66) | HSD17B10ROCK2MTORMEN1KMT2A | |
| SCHEMBL19377360 | 0.82 | HSD17B10 (0.52) | HSD17B10MTORITGB3ITGA2BMEN1 | |
| SCHEMBL531914 | 0.81 | NPC1 (0.66) | ITGB3ITGA2MELK | |
| SCHEMBL19377663 | 0.78 | HSD17B10 (0.49) | HSD17B10MTORITGB3ITGA2BMEN1 | |
| SCHEMBL19377218 | 0.78 | HSD17B10 (0.49) | HSD17B10MTORITGB3ITGA2BMEN1 | |
| SCHEMBL19377220 | 0.78 | HSD17B10 (0.49) | HSD17B10MTORITGB3ITGA2BMEN1 | |
| SCHEMBL19377382 | 0.77 | HSD17B10 (0.43) | HSD17B10ROCK2MTORITGB3ITGA2B | |
| SCHEMBL19377385 | 0.77 | HSD17B10 (0.43) | HSD17B10ROCK2MTORITGB3ITGA2B | |
| SCHEMBL19377243 | 0.76 | IDH1 (0.48) | HSD17B10MTORITGB3ITGA2B | |
| SCHEMBL19377007 | 0.76 | IDH1 (0.48) | HSD17B10MTORITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | HSD17B10 2852/4885ROCK2 4208/4885MTOR 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.